195 related articles for article (PubMed ID: 24314055)
21. The influence of different contrast medium concentrations and injection protocols on quantitative and clinical assessment of FDG-PET/CT in lung cancer.
Verburg FA; Kuhl CK; Pietsch H; Palmowski M; Mottaghy FM; Behrendt FF
Eur J Radiol; 2013 Oct; 82(10):e617-22. PubMed ID: 23880426
[TBL] [Abstract][Full Text] [Related]
22. F-18 FDG PET/CT in the evaluation of Takayasu arteritis: an experience from the tropics.
Santhosh S; Mittal BR; Gayana S; Bhattacharya A; Sharma A; Jain S
J Nucl Cardiol; 2014 Oct; 21(5):993-1000. PubMed ID: 24875577
[TBL] [Abstract][Full Text] [Related]
23. Fluorodeoxyglucose positron emission tomography with computed tomography detects greater metabolic changes that are not represented by plain radiography for patients with osteonecrosis of the jaw.
Fleisher KE; Raad RA; Rakheja R; Gupta V; Chan KC; Friedman KP; Mourtzikos KA; Janal M; Glickman RS
J Oral Maxillofac Surg; 2014 Oct; 72(10):1957-65. PubMed ID: 25053572
[TBL] [Abstract][Full Text] [Related]
24. Spatial and temporal heterogeneity of regional myocardial uptake in patients without heart disease under fasting conditions on repeated whole-body 18F-FDG PET/CT.
Inglese E; Leva L; Matheoud R; Sacchetti G; Secco C; Gandolfo P; Brambilla M; Sambuceti G
J Nucl Med; 2007 Oct; 48(10):1662-9. PubMed ID: 17873124
[TBL] [Abstract][Full Text] [Related]
25. F-18 FDG PET/CT in the management of thyroid cancer.
Iagaru A; Kalinyak JE; McDougall IR
Clin Nucl Med; 2007 Sep; 32(9):690-5. PubMed ID: 17710020
[TBL] [Abstract][Full Text] [Related]
26. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
[TBL] [Abstract][Full Text] [Related]
27. Whole-body MR-DWIBS vs. [18F]-FDG-PET/CT in the study of malignant tumors: a retrospective study.
Cafagna D; Rubini G; Iuele F; Maggialetti N; Notaristefano A; Pinto D; Niccoli-Asabella A; Palmiotti G; Lasciarrea M; Maggialetti A
Radiol Med; 2012 Mar; 117(2):293-311. PubMed ID: 21744252
[TBL] [Abstract][Full Text] [Related]
28. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes.
Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H
Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992
[TBL] [Abstract][Full Text] [Related]
29. 18-F fluorodeoxyglucose uptake in positron emission tomography as a pathological grade predictor for renal clear cell carcinomas.
Noda Y; Kanematsu M; Goshima S; Suzui N; Hirose Y; Matsunaga K; Nishibori H; Kondo H; Watanabe H; Kawada H; Kawai N; Tanahashi Y; Bae KT
Eur Radiol; 2015 Oct; 25(10):3009-16. PubMed ID: 25854217
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
Gatidis S; Schmidt H; Gücke B; Bezrukov I; Seitz G; Ebinger M; Reimold M; Pfannenberg CA; Nikolaou K; Schwenzer NF; Schäfer JF
Invest Radiol; 2016 Jan; 51(1):7-14. PubMed ID: 26309185
[TBL] [Abstract][Full Text] [Related]
31. Prone Versus Supine Breast FDG-PET/CT for Assessing Locoregional Disease Distribution in Locally Advanced Breast Cancer.
Abramson RG; Lambert KF; Jones-Jackson LB; Arlinghaus LR; Williams J; Abramson VG; Chakravarthy AB; Yankeelov TE
Acad Radiol; 2015 Jul; 22(7):853-9. PubMed ID: 25865435
[TBL] [Abstract][Full Text] [Related]
32. Impact of Pretreatment Combined (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer.
Ng SP; David S; Alamgeer M; Ganju V
Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):111-7. PubMed ID: 26279029
[TBL] [Abstract][Full Text] [Related]
33. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
[TBL] [Abstract][Full Text] [Related]
34. PET/MRI with diagnostic MR sequences vs PET/CT in the detection of abdominal and pelvic cancer.
Xin J; Ma Q; Guo Q; Sun H; Zhang S; Liu C; Zhai W
Eur J Radiol; 2016 Apr; 85(4):751-9. PubMed ID: 26971419
[TBL] [Abstract][Full Text] [Related]
35. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
36. The value of 18F-FDG PET in pediatric patients with post-transplant lymphoproliferative disorder at initial diagnosis.
Vali R; Punnett A; Bajno L; Moineddin R; Shammas A
Pediatr Transplant; 2015 Dec; 19(8):932-9. PubMed ID: 26515450
[TBL] [Abstract][Full Text] [Related]
37. Multimodal imaging and detection approach to 18F-FDG-directed surgery for patients with known or suspected malignancies: a comprehensive description of the specific methodology utilized in a single-institution cumulative retrospective experience.
Povoski SP; Hall NC; Murrey DA; Chow AZ; Gaglani JR; Bahnson EE; Mojzisik CM; Kuhrt MP; Hitchcock CL; Knopp MV; Martin EW
World J Surg Oncol; 2011 Nov; 9():152. PubMed ID: 22112047
[TBL] [Abstract][Full Text] [Related]
38. 18F-FDG PET/CT evaluation of children and young adults with suspected spinal fusion hardware infection.
Bagrosky BM; Hayes KL; Koo PJ; Fenton LZ
Pediatr Radiol; 2013 Aug; 43(8):991-1000. PubMed ID: 23455308
[TBL] [Abstract][Full Text] [Related]
39. Incidental abnormal FDG uptake in the prostate on 18-fluoro-2-deoxyglucose positron emission tomography-computed tomography scans.
Kang PM; Seo WI; Lee SS; Bae SK; Kwak HS; Min K; Kim W; Kang DI
Asian Pac J Cancer Prev; 2014; 15(20):8699-703. PubMed ID: 25374193
[TBL] [Abstract][Full Text] [Related]
40. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
Salem SS; Shahin MA
Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
